TY - JOUR PY - 2022// TI - Prevention of violence against women and girls: a cost-effectiveness study across 6 low- and middle-income countries JO - Public Library of Science medicine A1 - Ferrari, Giulia A1 - Torres-Rueda, Sergio A1 - Chirwa, Esnat A1 - Gibbs, Andrew A1 - Orangi, Stacey A1 - Barasa, Edwine A1 - Tawiah, Theresa A1 - Dwommoh Prah, Rebecca Kyerewaa A1 - Hitimana, Regis A1 - Daviaud, Emmanuelle A1 - Kapapa, Eleonah A1 - Dunkle, Kristin A1 - Heise, Lori A1 - Stern, Erin A1 - Chatterji, Sangeeta A1 - Omondi, Benjamin A1 - Ogum Alangea, Deda A1 - Karmaliani, Rozina A1 - Maqbool Ahmed Khuwaja, Hussain A1 - Jewkes, Rachel A1 - Watts, Charlotte A1 - Vassall, Anna SP - e1003827 EP - e1003827 VL - 19 IS - 3 N2 - BACKGROUND: Violence against women and girls (VAWG) is a human rights violation with social, economic, and health consequences for survivors, perpetrators, and society. Robust evidence on economic, social, and health impact, plus the cost of delivery of VAWG prevention, is critical to making the case for investment, particularly in low- and middle-income countries (LMICs) where health sector resources are highly constrained. We report on the costs and health impact of VAWG prevention in 6 countries.

METHODS AND FINDINGS: We conducted a trial-based cost-effectiveness analysis of VAWG prevention interventions using primary data from 5 randomised controlled trials (RCTs) in sub-Saharan Africa and 1 in South Asia. We evaluated 2 school-based interventions aimed at adolescents (11 to 14 years old) and 2 workshop-based (small group or one to one) interventions, 1 community-based intervention, and 1 combined small group and community-based programme all aimed at adult men and women (18+ years old). All interventions were delivered between 2015 and 2018 and were compared to a do-nothing scenario, except for one of the school-based interventions (government-mandated programme) and for the combined intervention (access to financial services in small groups). We computed the health burden from VAWG with disability-adjusted life year (DALY). We estimated per capita DALYs averted using statistical models that reflect each trial's design and any baseline imbalances. We report cost-effectiveness as cost per DALY averted and characterise uncertainty in the estimates with probabilistic sensitivity analysis (PSA) and cost-effectiveness acceptability curves (CEACs), which show the probability of cost-effectiveness at different thresholds. We report a subgroup analysis of the small group component of the combined intervention and no other subgroup analysis. We also report an impact inventory to illustrate interventions' socioeconomic impact beyond health. We use a 3% discount rate for investment costs and a 1-year time horizon, assuming no effects post the intervention period. From a health sector perspective, the cost per DALY averted varies between US$222 (2018), for an established gender attitudes and harmful social norms change community-based intervention in Ghana, to US$17,548 (2018) for a livelihoods intervention in South Africa. Taking a societal perspective and including wider economic impact improves the cost-effectiveness of some interventions but reduces others. For example, interventions with positive economic impacts, often those with explicit economic goals, offset implementation costs and achieve more favourable cost-effectiveness ratios.

RESULTS are robust to sensitivity analyses. Our DALYs include a subset of the health consequences of VAWG exposure; we assume no mortality impact from any of the health consequences included in the DALYs calculations. In both cases, we may be underestimating overall health impact. We also do not report on participants' health costs.

CONCLUSIONS: We demonstrate that investment in established community-based VAWG prevention interventions can improve population health in LMICs, even within highly constrained health budgets. However, several VAWG prevention interventions require further modification to achieve affordability and cost-effectiveness at scale. Broadening the range of social, health, and economic outcomes captured in future cost-effectiveness assessments remains critical to justifying the investment urgently required to prevent VAWG globally.

Language: en

LA - en SN - 1549-1277 UR - http://dx.doi.org/10.1371/journal.pmed.1003827 ID - ref1 ER -